Skip to main content
Clinical Trials/NCT03782519
NCT03782519UnknownNot Applicable

Quality of Life of Frail Aged Patients in Incremental Hemodialysis: a Phase III Study

Centre Hospitalier Universitaire de Besancon1 site in 1 country783 target enrollmentStarted: May 9, 2019Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Enrollment
783
Locations
1
Primary Endpoint
Mental and physical health summary scores of the Medical Outcome Study - Short Form 36 (MOS SF-36)

Study Overview

Brief Summary

End stage renal disease (ESRD) is a major public health problem. The dialysis population is aging. As a result we observe a high prevalence of frailty among dialysis patients (ranges from 3 to 10 fold higher than in the comparably aged general public). Frailty is a medical syndrome characterized by diminished strength, endurance, and reduced physiologic function that increases an individual's vulnerability for developing increased dependency and/or death. Without systematic approach it is difficult for physicians to detect frailty phenotype which however might be reversible or attenuated by interventions. Fried et al. developed a frailty phenotype consisting of 3 or more of: unintentional weight loss, exhaustion, physical inactivity, slow gait speed, and weak grip strength. The primary care of hemodialysis patient is often supported by the nephrologist. Identification of frailty is integrated into the primary care setting as one of the steps necessary for the overall assessment of the person and planning to formal prevention interventions in an individualized care plan. Thrice-weekly hemodialysis (HD) schedules are the standard default hemodialysis prescription in Western countries, imposed in the 70s. For incremental HD, the weekly dose of dialysis is based on variety of clinical factors such as residual kidney function, volume status, cardiovascular symptoms, potassium level, nutritional status and, comorbid conditions. Incremental HD scheme generally starts with 2 weekly sessions and then periodic monitoring of criteria mentioned above are used to determine the timing for increasing dialysis dose and frequency to 3 weekly sessions.

An approach that integrates systematic frailty phenotype assessment by nephrologists and individualized incremental HD therapy can be beneficial within the first year of HD. It could optimize health-related quality of life and other pertinent outcomes without affecting negatively the quality of dialysis. The purpose of this study is to evaluate for frail aged incidents hemodialysis patients the impact of implementation of an incremental HD on HRQoL compared to conventional HD.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Supportive Care
Masking
None

Eligibility Criteria

Ages
60 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •For all patients (incident HD patients):
  • •Patient aged over 60 years
  • •Signature of informed consent
  • •Affiliation to a French social security or receiving such a scheme
  • •Patient with Chronic Kidney Disease Stage 5 (GFR <15 ml/min/1.73m2)
  • •Urine output > 0,5 L per day
  • •Kru ≥ 2 ml/min
  • •Outpatient with scheduled start of HD
  • •Understand and read french
  • •For randomized patients (frail incident HD patients):
  • •Frailty according to L. Fried criteria: score greater than or equal to 3/5

Exclusion Criteria

  • •Inability to understand the reasons for the study; psychiatric disorders
  • •Active and/or treated neoplastic disease
  • •Scheduled kidney transplantation within 6 months
  • •Solid organ transplanted patient receiving immunosuppressive therapy
  • •Estimated life expectancy < 6 months
  • •Patient with diagnosis of severe chronic heart failure (> 2 congestive heart failure episodes requiring hospitalization in the year preceding the start of HD)
  • •Legal disability or limited legal capacity
  • •Patient without health insurance
  • •Patient in the period of exclusion of another study
  • •Uncooperative patient

Arms & Interventions

Incremental hemodialysis

Experimental

Patients who will begin HD with two treatment sessions per week

Intervention: Dialysis frequency reduction (Other)

Incremental hemodialysis

Experimental

Patients who will begin HD with two treatment sessions per week

Intervention: Frailty diagnosis (Other)

Conventional hemodialysis

Active Comparator

Patients who will begin HD three times a week

Intervention: Frailty diagnosis (Other)

Outcomes

Primary Outcomes

Mental and physical health summary scores of the Medical Outcome Study - Short Form 36 (MOS SF-36)

Time Frame: One year after the initiation of HD

Symptom/problem, effects of kidney disease and burden of kidney disease dimensions of the Kidney Disease Quality of Life (KDQOL)

Time Frame: One year after the initiation of HD

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials